Entrada Therapeutics

Glucarpidase treatment significantly improves kidney recovery in methotrexate-associated AKI patients, with a 2.7-fold increase in recovery odds, faster recovery time, and reduced risks of neutropenia and transaminitis. Benefits were more pronounced in females and stage 3 AKI patients. The study, involving 708 patients from 28 centers, highlights glucarpidase's potential beyond methotrexate level reduction, despite its high cost and varied hospital usage.

In 2024, Muscular Dystrophy News Today highlighted key developments in MD research, including gene therapy trials, new treatments like SAT-3247 and Elevidys, and clinical advancements for DMD and FSHD, emphasizing progress in muscle function and dystrophin production.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.